Introduction
Progressive myoclonus epilepsies (PMEs) are a group of rare inherited disorders characterized by the association of epilepsy, myoclonus and progressive neurological deterioration [1] . Oxidative stress, recognized as one of the predisposing factors in various neurological disorders, is suggested as an important factor in this process [2] [3] [4] [5] . It has long been known that oxidative stress may contribute to neuronal hyperexcitability, while antioxidants may alleviate the progression of PME [2, 3, 6] . Furthermore, an improvement in the general condition and even reduction of seizures and myoclonus by antioxidants has been reported in both familial and non-related patients with the same PME syndrome [2, 3, 6] . Still, the molecular mechanisms underlying oxidative stress and its role in progressive myoclonus epilepsy remain elusive.
Oxidative reactions occurring in mitochondria produce oxygen radicals physiologically in nervous system cells. If a strong antioxidant defense system is present in the cells, they will be protected from the damaging effects of reactive oxygen species [7, 8] . Glutathione S-transferases (GSTs) are a superfamily of enzymes involved in both protection from oxidative damage and detoxification [9] . Furthermore, they play an important role in metabolizing antiepileptic drugs (AEDs) in liver [10, 11] . Namely, many conventional AEDs undergo metabolism generating active metabolites, including epoxides, which might have effect on suppression of epileptic spike, but unfortunately, also in systemic toxicity via epoxide-induced covalent binding to proteins and lipids [10, 12] . Glutathione S-transferases play an important role in catalyzing the conjugation of these metabolites to glutathione, especially in the removal of epoxide metabolites that are generated during the metabolism of AEDs. Apart from decreasing their toxicity and facilitating their excretion from the body, it is assumed that this way GSTs may also affect the response to anticonvulsant therapy [10] .
The most characterized GST classes have been named alpha (GSTA), mu (GSTM), pi (GSTP) and theta (GSTT). Almost all members of GST family exhibit genetic polymorphism, resulting in complete lack or lowering of enzyme activity [9] . Consequently, individuals lacking certain GST isoenzyme activity may have altered capacity for protecting tissues from exogenous and endogenous oxidants, as well as, AEDs [13] . In agreement with this assumption are the results of Liu and Tsai on enhanced lipid peroxidation in patients with GSTM1-null genotype and intractable seizure [10] . Another member of GST family, GSTP1, has been associated with resistance to AEDs treatment. Namely, high levels of GSTP1 expression in endothelial cells and glial cells/ astrocytes have been shown to correlate to medical intractable epilepsy [11] . Furthermore, the lack of GSTT1 has been associated with susceptibility to brain diseases, including neurodegenerative diseases [14] . Still, the potential role of genetic polymorphism of GSTs in both risk for development and resistance to AEDs therapy in patients with PME has to be established.
This has prompted us to assess a possible association between GST polymorphism and progressive myoclonus epilepsy. Whether the null or low-activity GSTA1, GSTM1, GSTP1 and GSTT1genotypes, alone or in combination, correlate with biomarkers of oxidative stress in patients with progressive myoclonus epilepsy will be additionally evaluated.
Methods

Study participants
Genomic DNA was isolated from 26 patients (13 male and 13 female, mean age 20 AE 7.04 years) with progressive myoclonus epilepsy. Five patients had Unverricht-Lundborg disease, fourteen Lafora body disease, another five myoclonic epilepsy with ragged red fibers and 2 had late infantile neuronal ceroid lipofuscinosis. Patients were diagnosed based on the clinical history, electrophysiological findings and confirmed by molecular genetic studies.
The seizure types in these patients were generalized tonicclonic seizures and myoclonus. All patients were on valproic acid with multiple other antiepileptic drug regimens. Control group consisted of 66 healthy, non-epileptic subjects, without any drug treatment, matched for sex, age, ethnicity and geographic origin.
All the participants and/or their parents provided written informed consent. This study protocol was approved by the Institutional Review Board, and the research was carried out in compliance with the Helsinki Declaration (as revised in 2000).
Molecular genetic studies
Using PCR protocol with betaine, we amplified promoter region of the CSTB gene. After separation of amplified products in 2% agarose gel along with DNA size standard, we detected a homozygous expansion of dodecamer repeats in four ULD patients [15] . Molecular diagnostics of LD, MERRF and NCL patients was performed by sequencing coding regions of appropriate genes.
GST genotyping
Genomic DNA was isolated from whole blood using the QIAGEN QIAmp kit (Qiagen, Inc., Chatsworth, CA). GSTA1 C-69T polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) by Ping et al. [16] . The presence of restriction site resulting in two fragments (481 and 385 bp) indicated mutant allele (T/T) and if C/T polymorphism incurred, it resulted in one more fragment of 96 bp (Fig. 1a) .
GSTM1 genotyping was performed by multiplex PCR [17] . Exon 7 of the CYP1A1 gene was co-amplified and used as an internal control. The presence of the GSTM1 active genotype was detected by the band at 215 bp, since the assay does not distinguish heterozygous or homozygous wild-type genotypes (Fig. 1b) .
GSTP1 Ile105Val polymorphism was analyzed using the PCR-RFLP method by Harries et al. [18] . The presence of restriction site resulting in two fragments (91 and 85 bp) indicated mutant allele (Val/Val), while if Ile/Val polymorphism incurred, it resulted in one more fragment of 176 bp (Fig. 1c) .
GSTT1 genotyping was performed by multiplex PCR [17] . The assay does not distinguish between heterozygous or homozygous wild-type genotypes; therefore, the presence of 480 bp bands was indicative for the GSTT1 active genotype (Fig. 1d) .
Biomarkers of oxidative stress in plasma
The amount of plasma thiol (P-SH) groups was determined according to the method of Jocelyn and expressed as mmol/g of proteins (mmol/g prot) [19] . Nitrotyrosine content was measured by enzyme immunoassay (OxiSelectTM ELISA kits, Cell Biolabs). Cu, Zn SOD activity in the plasma was measured by the method of Misra and Fridovich, based on the ability of SOD to inhibit autooxidation of epinephrine at alkaline pH (pH 10.2) [20] . GPX activity was determined by the coupled assay procedure of Gunzler et al. [21] .
Statistical analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences software (IBM Statistics SPSS, version 20.0). In descriptive statistics, we summarized all continuous variables by means AE standard deviations (SD). The relative associations between the studied genotypes and PME risk were evaluated by multinomial logistic regression to calculate odds ratios (OR) and corresponding 95% confidence intervals (CI), adjusted according to age and gender as potential confounding factors. Differences in investigated biomarkers of oxidative stress were assessed by using x 2 test. Statistical evaluation of relationships between biomarkers of oxidative stress (SH groups, nitrotyrosine, superoxide dismutase and glutathione peroxidase) and GST genotypes in PME patients was performed by using the Mann-Whitney rank-sum test (for betweentwo-group comparisons) and the Kruskal-Wallis non-parametric test that compared three unpaired groups. Two-tailed p-values of <0.05 were considered statistically significant.
The Bonferroni post hoc test was performed for locating differences between multiple groups, if it was necessary.
Results
GST genotype and PME risk
The distribution of GST genotypes in patients with progressive myoclonus epilepsy and controls is presented in Table 1 .
The frequency of GSTA1, GSTM1 and GSTP1 genotypes was not significantly different in PME patients in comparison to controls. Although it seems that in case of GSTA1 polymorphism, lowactivity (T) allele might have some effect on decreasing the risk for PME, statistical significance was not reached. Significant association between the GST genotype and risk of PME was found only for the GSTT1 genotype. Namely, individuals with GSTT1-null genotype were at 5.44-fold higher risk of PME (OR = 5.44, 95% CI = 2.04-14.46, p = 0.001) than individuals carrying the GSTT1-active genotype.
When GST genotypes were analyzed in combination (Table 2) , the significant risk of PME was obtained in subjects who carried both GSTT1-null and GSTM1-null genotypes (OR = 6.28, 95% CI = 1.70-23.13, p = 0.006), which was preserved after Bonferroni correction. Combination of GSTT1-null with the GSTP1-low-activity genotype was also found to be significant (OR = 4.28, 95% CI = 1.17-15.57, p = 0.027), however the risk for PME was lower than in case of individual GSTT1-null genotype. Furthermore, after Bonferroni correction statistical significance was nullified. Interestingly, when GSTT1-null genotype was combined with both active and low-activity GSTA1 genotype, 7.55 and 5.03 fold higher risk for PME was obtained (OR = 7.55, 95% CI = 1.49-38.02, p = 0.014 and OR = 5.03, 95% CI = 1.06-23.81, p = 0.041, respectively). Since in case of combined active GSTA1 and GSTT1-null genotype even after Bonferroni correction statistical significance was preserved, it practically means that carriers of combined active GSTA1 and GSTT1-null genotype are at highest risk for development of progressive myoclonus epilepsy. On the other hand, similarly to combined GSTT1-null and GSTP1-low-activity genotype, the risk for PME in carriers of combined GSTA1 low-activity and GSTT1-null genotype was lower than in case of individual GSTT1-null genotype. Table 3 summarizes the data on the degree of oxidative and nitrosative damage to proteins, as well as, major antioxidant enzyme activities in patients with PME. Although plasma protein thiol groups content was lower and nitrotyrosine was found to be higher in patients with PME in comparison to healthy controls, this change in byproducts of protein damage did not reach statistical significance. However, the activities of antioxidant enzymes, superoxide dismutase and glutathione peroxidase, were found to be statistically significantly higher in PME patients when compared to controls (p = 0.003 and 0.005, respectively; Table 3) .
Association between GST genotype and biomarkers of oxidative stress
Results obtained when biomarkers of oxidative stress were stratified according to GST genotypes are presented in Table 4 . Plasma protein thiol groups concentration was lower in patients with GSTM1-null, as well as, GSTT1-null genotypes in comparison to corresponding active genotypes, however statisticall significance was reached only in patients with GSTT1-null genotype (p = 0.042). After Bonferroni correction the observed statistical significance was nullified. Although nitrotyrosine, a reliable marker of nitrosative damage of proteins, was found to be higher in patients with the GSTM1-null genotype in comparison to GSTM1 active genotype, this increase did not reach statistical significance (p = 0.089).
Regarding antioxidant enzyme activities, only SOD, when stratified according to GSTT1 polymorphisms, showed change in activity (p = 0.055). Namely, SOD activity was found to be increased in GSTT1-null when compared to corresponding active genotype, however statistically unsignificant.
Discussion
Based on the premise that oxidative stress is associated with pathogenesis and progression of progressive myoclonus epilepsy [2] [3] [4] [5] , we speculated that variations in antioxidant and detoxifying activities of glutathione S-transferases might modulate individual tendency toward PME development. Among four GST polymorphisms analyzed in this study, only the GSTT1-null genotype has shown a significant association with PME that was even more pronounced if GSTM1-null genotype was also present. When GSTT1-null genotype is associated with remaining two GST genotypes, GSTA1 and GSTP1, the risk for PME development is shown to be increased in carriers of both active and low-activity genotypes. To our knowledge, this is the first investigation that addressed the association of common GST polymorphisms and PME.
As suggested, susceptibility to progressive myoclonus epilepsy might depend on expression profiles of enzymes involved in both protection from oxidative damage and detoxification [9] [10] [11] . Indeed, individuals lacking certain GST isoenzyme activity may have altered capacity for protecting tissues from exogenous and endogenous oxidants [13] . Polymorphism of GSTT1, the only GST polymorphism which might be independently associated to PME risk, has so far been mostly related to risk of various human cancers [14] . Interestingly, although not confirmed in all the studies, the lack of GSTT1 is associated with increased susceptibility to brain tumors, such as astrocytoma, meningeoma, oligodendroglioma, but also neurodegenerative diseases [22] [23] [24] . Namely, the lack of GSTT1 activity was associated with an increased risk of Alzheimer's disease, Parkinson's disease and motor neuron disease Combined effects of GST genotypes in relation to the risk of PME. in males [24] . Due to the fact that these data were obtained in individuals unexposed to neurotoxins, it might be hypothesized that the metabolism of neurotoxins or other endogenous substances can vary in different GSTT1 backgrounds, affecting the risk of diseases in the central nervous system. Another GST polymorphism, GSTM1-null, was shown to increase risk for PME development in our study, however only when combined with GSTT1-null genotype. Glutathione S-transferase M1 has so far been associated with enhanced oxidative damage to lipids and poor response to antiepileptic drugs in patients with epilepsy [10] . However, Shang et al. have reported no significant association between GSTM expression in brains of patients with intractable epilepsy with failure to response to AEDs [11] . In general, GSTM1-null and GSTM1-null/GSTT1-null genotypes have so far, in patients with any type of epilepsy, been mostly investigated as risk factors for carbamazepine (CBZ) and valproic acid (VPA)-induced hepatotoxicity [25, 26] .
GSTT1 GSTA1
Alpha class of GSTs, which interestingly affects the risk for PME development when in combination with GSTT1-null genotype, in carriers of both active and low-activity GSTA1 genotypes, has been evaluated only in pregnant woman with epilepsy [27] and in patients with medically intractable seizures, where its expression was not found in brain [11] . This result is rather unusual, since alpha class GSTs are widely expressed in most tissues, including brain [28] . Dieckhaus et al. have investigated the role of GSTA in terms of detoxification of 2-phenylpropenal, a reactive felbamate metabolite which was considered effective therapy for refractory epilepsy, but limited due to the associated reports of hepatotoxicity and aplastic anemia [29] . However, no significant association was found. Taken together, the only possible explanation for the effect on the risk for developing PME might be in the potential role of GSTA1 in bioactivation of certain neurotoxic compounds. Namely, although GSTs constitute an important part of the cellular detoxification system through the conjugation of glutathione (GSH) with genotoxic substrates, they are also responsible for the bioactivation of several drugs, for example, TLK-286, brostallicin and thiopurines such as Azathioprine, which has been used in organ transplantation and in the treatment of autoimmune diseases and cancer for decades [30] .
Situation is rather similar with GSTP1 polymorphism, which also affects the risk for PME development only in combination with GSTT1-null genotype. Still, expression of GSTP1 was found to be significantly higher in brain specimens from patients with epilepsy, than in controls [11] . Furthermore, Deng et al. have found that the change in expression of GSTP in peripheral blood shows the same pattern as that in brain tissues, suggesting GSTP might contribute to drug resistance in epilepsy, suggesting that the GSTP over-expression in peripheral blood could be used as a marker for resistance to anti-epileptic agents [31] .
The assumption that lacking or low-activity GST gene variants might contribute to increased susceptibility to oxidative stress in patients with PME has been partially confirmed in the next phase of this investigation, in which the influence of polymorphic GSTA1, GSTM1, GSTP1 and GSTT1 genes was analyzed with respect to oxidative phenotype. Namely, all products of analyzed GST genes possess both glutathione conjugating and antioxidant enzymatic activity [9] . However, according to the results presented in this study, the level of protection against oxidative stress in progressive myoclonus epilepsy might be influenced by common GST polymorphisms which determine the quantity and/or activity of GST protein 'echelons' that act upon accumulated harmful compounds.
Oxidative damage to proteins is one of the major mechanisms underlying neuronal cell damage [32] . We demonstrated that the concentration of protein sulfhydryl groups in plasma, which are important chain breaking antioxidant [32] is reduced in patients with PME. Decreased P-SH levels may be a consequence of enhanced free radicals production in epileptic seizure, since sulfhydryl groups of plasma proteins have been suggested to be a ''sacrificial'' antioxidant in plasma and extravascular spaces [33] . Results on decreased P-SH content in patients with PME are in agreement with our previous findings obtained in patients with partial cryptogenic and generalized idiopathic epileptic seizures [34] . Further analysis, based on association to different GST genotypes, showed that decrease in P-SH levels was the most obvious in patients carrying either GSTM1-null or GSTT1-null genotype. It means that individual GST polymorphisms influence vulnerability to protein oxidation, with GSTM1-null or GSTT1-null gene variants having the most pronounced effect in patients with PME. This might be explained by the fact that individuals with the GSTM1-null/GSTT1-null genotype have lower total antioxidant capacity than those with both active genotypes, as suggested by Tang et al. [35] . Nitrotyrosine, a reliable marker of nitrosative damage to proteins, was found to be higher in patients with progressive myoclonus epilepsy. Although the association between GST null or low-activity gene variants and plasma Table 4 Biomarkers of oxidative stress in relation to GST genotypes in patients with PME. nitrotyrosine level in PME patients was relatively mild, our findings suggest that their antioxidant activities, especially GSTM1 polymorphism, at least partially affect the level of nitrosative damage.
The question that arises is how antioxidant enzymes contribute to oxidative phenotype in patients with PME. Extracellular SOD represents a major defense system against superoxide, being also a target for oxidative damage [36] . Hurd et al. have reported an increase in serum extracellular SOD activity in the progressive myoclonus epilepsies [37] . Similar findings were reported by BenMenachem et al. who found increased plasma SOD activity, but decreased erythrocyte SOD activity in patients with PME [3] . Our results on significant increase in plasma SOD activity in patients with PME are in agreement with these findings. Furthermore, when SOD activity was analyzed in relation to GST genotypes, the association was found only in case of GSTT1 polymorphisms. Therefore, it seems that individuals who lack GSTT1 enzyme activity have higher SOD activity as an adoptive phenomenon compensating increased oxidative stress, that implies possible genetic predisposition to worse oxidative phenotype. Contrary to these findings, Wu et al. have shown that in patients with myoclonus epilepsy with ragged-red fibers syndrome levels of mitochondrial SOD were increased, while extracellular SOD remained unchained [38] .
The data on another antioxidant major enzyme, GPX, in patients with PME are rather limited. Extracellular GPX is presumed to work as a part of a traditional glutathione cycle [39] . The tripeptide glutathione is involved in disposal of peroxides by brain cells and in protection against reactive oxygen species, while its content in brain cells depends strongly on the availability of precursors for glutathione [40] . The pattern of changes observed in our study for plasma GPX activity in patients with PME resembles that of SOD. Namely, we have shown a significant increase in plasma GPX activity in patients with PME, although it could not be associated to any of analyzed GST genotypes. Our findings are in contrast to BenMenachem et al. who have found no significant change in GPX activity in patients with Unverricht-Lundborg and Lafora body disease in comparison to healthy individuals [3] . In that line, Wu et al. also found no significant change in GPX activity in cultured cells of patients with myoclonus epilepsy with ragged-red fibers syndrome [38] .
Based on the results of this investigation it may be concluded that presence of GSTT1-null genotype might be associated with the increased risk of PME development and enhanced susceptibility to oxidative stress in these patients. The effect is most pronounced if GSTT1-null and GSTM1-null genotypes are present in combination in patients with PME. In addition to risk, our results may have implications in new approaches to the antioxidant therapy in patients with PME. Namely, taken together, these results suggest a possibility for GST genotype based stratification of patients with PME which could improve the attempts toward the individualization of the antioxidant treatment. Since susceptibility to oxidative damage differs with respect to GST genotype, it seems reasonable to assume that individuals' GST ''genetic profile'', in addition to plausible oxidative stress biomarkers, should be also considered in optimization of form, dose and time course of antioxidant treatment. So far, high doses of N-acetylcysteine (NAC), a glutathione precursor, have been shown to markedly improve and stabilize neurological condition in patients with UnverrichtLundborg disease [2, 3] , while the effect was doubtful in case of Lafora body disease [3] . Furthermore, Edwards et al. have shown that increase in glutathione levels during treatment with NAC was followed by an improvement in seizures, but not in myoclonus or ataxia in patients with PME [6] . Hachiya et al. also suggested usage of antioxidant agents in treatment of neuronal ceroid-lipofuscinoses [41] .
Certain limitations might be considered in our study. The casecontrol design was used for estimating of associations between GST genotypes and PME development and therefore the selection bias might influence the results. Due to a limited number of patients with different types of PME, it was not possible to evaluate association between specific types of progressive myoclonus epilepsy and biomarkers of oxidative stress. Furthermore, evaluation of polymorphic expression of GSTs in terms of specific PME outcome might provide information that could affect the treatment of these patients, however, on much larger study population. A meta-analysis of previously published studies might contribute to interpretation of findings in this study, however no other studies of association between GSTA1, GSTM1, GSTP1 and GSTT1 polymorphisms and PME exist. Still, although the sample size is rather small, this study may offer some essential information that could be the base for future longitudinal research.
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